Fig 1.
Flow cytometric analysis of CD39 and PD1 expression by the T Lymphocyte subsets.
A: The lymphocyte population was gated from peripheral blood mononuclear cells by drawing (R1) based on the forward/side scatter characteristics. B, C: CD3 expression was analysed on the gated lymphocytes, and the CD3+ cells were selected by (R2) for further analysis based on CD4 and CD8 expression. (R3) and (R4) represent the regions used to choose the CD4+ andCD8+T cells, respectively. D-H: Dot plots representing CD39 and PD1 expression by CD4+ andCD8+ T cells.
Fig 2.
Disease-free survival (DFS) among 30 patients with triple-negative breast cancer (TNBC).
Table 1.
Clinico-pathological parameters of 30 females with TNBC.
Table 2.
Differential expression of PD1 and CD39 on T lymphocytes in tumor and normal breast tissue of patients with triple-negative breast cancer.
Fig 3.
DFS association with tumor-infiltrating (A) PD1+CD8+ T lymphocytes (p = 0.007), and (B) CD39+CD8+ T lymphocytes (p = 0.03), in 30 TNBC patients.
Fig 4.
Differences in the mean percentages of tumor-infiltrating PD1+CD4+ T lymphocytes according to local recurrence (p = 0.03) for the 30 patients with TNBC (Independent t-test).
Table 3.
Differential expression of PD1 and CD39 on peripheral blood T lymphocytes among patients with triple-negative breast cancer and controls.
Fig 5.
Correlation of peripheral PD1+CD8+ T lymphocytes with DFS in 30 TNBC patients (p = 0.04).
Fig 6.
Significant differences in the mean percentages of PD1+CD8+ (p = 0.03) and CD39+CD8+ peripheral T lymphocytes (p = 0.04) according to pathologic type (ILC, and IDC respectively), in 30 patients with TNBC (Independent t-test).
Table 4.
Differential expression of PD1 and CD39 among tumor-infiltrating and peripheral blood lymphocytes of patients with triple-negative breast cancer.
Table 5.
Correlations between tumor tissue and peripheral T lymphocyte subsets in patients with triple-negative breast cancer.
Fig 7.
Forest plot of HR for different lymphocyte subsets.
Table 6.
Cox regression analysis of DFS of 30 females with TNBC.